EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps

Anju T Peters, Jayant M Pinto, Kathleen M Buchheit, Sietze Reitsma, Andrew Thamboo, Shigeharu Fujieda, Mark Corbett, Eric Zaccone, Amr Radwan, Paul J Rowe, Yamo Deniz

Allergy and Asthma Proceedings · 01.09.2025 · 46 (5) · 406-413

DOI: 10.2500/aap.2025.46.250050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy and Asthma Proceedings, erschienen am 01.09.2025. Verfasst von Anju T Peters und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Adrenal Cortex Hormones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Systemic corticosteroids (SCS) are widely used to treat patients with chronic rhinosinusitis with nasal polyps (CRSwNP) that is insufficiently controlled with first-line treatments. However, such treatment must be balanced against the risk of adverse effects with protracted or repeated use. Increasing awareness of these adverse effects and the introduction of biologics are changing established management approaches.

Objective

The objective was to review the role of SCS in the management of CRSwNP in the evolving treatment landscape.

Methods

A literature search was conducted for salient articles on SCS in CRSwNP, including guidelines.

Results

SCS reduce inflammation through broad actions on various immune mediators. Short courses of SCS improve symptoms (especially olfactory function) and reduce polyp size, benefits that do not persist long-term after treatment ends. SCS are widely used before endoscopic sinus surgery to improve the visibility of the surgical field and after surgery to improve outcomes, although evidence for benefit of postsurgical SCS is lacking. Adverse effects associated with SCS can manifest in a wide range of organs and systems. Use of SCS in patients with CRSwNP is associated with an increased risk of avascular necrosis, pneumonia, obesity, anxiety and/or depression, fracture, sleep apnea, hypothalamic-pituitary-adrenal axis suppression, diabetes, and hypertension. The SCS dosage regimen for CRSwNP is not well defined, and there is wide variation in clinical practice. Clinical guidelines refer to “short courses” of SCS but provide minimal guidance and lack consensus. Biologic treatments for CRSwNP have well-documented steroid-sparing effects, but the extent to which biologics might be able to reduce the use of or replace SCS may depend on economics as well as relative benefit-to-risk ratios.

Conclusion

Short courses of SCS are widely used in patients with CRSwNP, but their use must be balanced against the risk of adverse effects. Use of biologics may reduce the use of SCS in CRSwNP, minimizing these adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisNasal PolypsRhinitisAdrenal Cortex HormonesHumansChronic DiseaseRhinosinusitis

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • From the Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
  • Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
  • Department of Otorhinolaryngology and Head/Neck Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Otorhinolaryngology, Head and Neck Surgery, University of Fukui, Fukui, Japan.

Förderung

  • NIEHS NIH HHS

Zitieren

APA

Peters, A. T., Pinto, J. M., Buchheit, K. M., Reitsma, S., Thamboo, A., Fujieda, S., Corbett, M., Zaccone, E., Radwan, A., Rowe, P. J., & Deniz, Y. (2025). The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps. Allergy and Asthma Proceedings, 46(5), 406-413. https://doi.org/10.2500/aap.2025.46.250050

Vancouver

Peters AT, Pinto JM, Buchheit KM, Reitsma S, Thamboo A, Fujieda S, et al. The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps. Allergy and Asthma Proceedings. 2025;46(5):406-413. doi:10.2500/aap.2025.46.250050

BibTeX
@article{Peters2025,
  author = {Peters, Anju T and Pinto, Jayant M and Buchheit, Kathleen M and Reitsma, Sietze and Thamboo, Andrew and Fujieda, Shigeharu and Corbett, Mark and Zaccone, Eric and Radwan, Amr and Rowe, Paul J and Deniz, Yamo},
  title = {The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps},
  journal = {Allergy and Asthma Proceedings},
  year = {2025},
  volume = {46},
  number = {5},
  pages = {406--413},
  doi = {10.2500/aap.2025.46.250050}
}
Kostenlos starten →